COVID-19 Study of Safety and Tolerability of Alvelestat

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18 years) with COVID-19 respiratory disease.

Timeline

Start

2021-01-25

Primary completion

2021-10-29

Completion

2021-10-29

Drugs

Indications